Curexo Inc (060280) - Total Liabilities

Latest as of September 2025: ₩9.36 Billion KRW ≈ $6.34 Million USD

Based on the latest financial reports, Curexo Inc (060280) has total liabilities worth ₩9.36 Billion KRW (≈ $6.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Curexo Inc - Total Liabilities Trend (2006–2024)

This chart illustrates how Curexo Inc's total liabilities have evolved over time, based on quarterly financial data. See 060280 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Curexo Inc Competitors by Total Liabilities

The table below lists competitors of Curexo Inc ranked by their total liabilities.

Company Country Total Liabilities
Dimand S.A.
AT:DIMAND
Greece €135.98 Million
Absolent Group AB
ST:ABSO
Sweden Skr702.63 Million
Dustin Group AB
ST:DUST
Sweden Skr8.12 Billion
Kalyani Investment Company Limited
NSE:KICL
India Rs10.43 Billion
Ege Gubre Sanayi AS
IS:EGGUB
Turkey TL1.99 Billion
Santhera Pharmaceuticals Holding AG
SW:SANN
Switzerland CHF159.90 Million
Anhui Hyea Aromas Co Ltd
SHE:300886
China CN¥130.08 Million

Liability Composition Analysis (2006–2024)

This chart breaks down Curexo Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Curexo Inc market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 11.22 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.10 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.09 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Curexo Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Curexo Inc (2006–2024)

The table below shows the annual total liabilities of Curexo Inc from 2006 to 2024.

Year Total Liabilities Change
2024-12-31 ₩9.20 Billion
≈ $6.24 Million
+32.58%
2023-12-31 ₩6.94 Billion
≈ $4.70 Million
-58.48%
2022-12-31 ₩16.72 Billion
≈ $11.33 Million
-9.17%
2021-12-31 ₩18.40 Billion
≈ $12.47 Million
+350.64%
2020-12-31 ₩4.08 Billion
≈ $2.77 Million
+29.84%
2019-12-31 ₩3.15 Billion
≈ $2.13 Million
-4.96%
2018-12-31 ₩3.31 Billion
≈ $2.24 Million
-31.91%
2017-12-31 ₩4.86 Billion
≈ $3.29 Million
-5.93%
2016-12-31 ₩5.17 Billion
≈ $3.50 Million
-79.43%
2015-12-31 ₩25.12 Billion
≈ $17.02 Million
-4.84%
2014-12-31 ₩26.39 Billion
≈ $17.89 Million
+492.85%
2013-12-31 ₩4.45 Billion
≈ $3.02 Million
+128.33%
2012-12-31 ₩1.95 Billion
≈ $1.32 Million
-96.50%
2011-12-31 ₩55.67 Billion
≈ $37.73 Million
+1417.14%
2010-12-31 ₩3.67 Billion
≈ $2.49 Million
-66.86%
2009-12-31 ₩11.07 Billion
≈ $7.50 Million
-5.03%
2008-12-31 ₩11.66 Billion
≈ $7.90 Million
-3.95%
2007-12-31 ₩12.14 Billion
≈ $8.23 Million
+29.52%
2006-12-31 ₩9.37 Billion
≈ $6.35 Million
--

About Curexo Inc

KQ:060280 Korea Food & Drug Retailing
Market Cap
$243.46 Million
₩359.26 Billion KRW
Market Cap Rank
#15864 Global
#564 in Korea
Share Price
₩10770.00
Change (1 day)
-0.92%
52-Week Range
₩7970.00 - ₩20350.00
All Time High
₩24400.00
About

Curexo Inc. engages in the development and sale of medical devices in Korea and internationally. Its products include ROBIN, a robot system that guides needle path induring CT-guided interventional procedure; Baidy, a medical device that assists labor by increasing intrauterine pressure which helps natural childbirth; artificial joint surgical robot; and Gait rehabilitation robot. The company als… Read more